BioCardia Q3 2026 net loss widens 20% to $1.8 million
BCDA•BioCardia’s third-quarter 2026 net loss widened 20% year over year to $1.8 million, while research and development expenses rose 28% to $1.2 million. The company reported $2.2 million in quarter-end cash and anticipated runway into 2027.
1. Quarterly results and plans
BioCardia’s third-quarter 2026 net loss widened 20% year over year to $1.8 million, and research and development expenses rose 28% to $1.2 million. Quarter-end cash and cash equivalents totaled $2.2 million, providing anticipated runway into 2027. The company targeted a CardiAMP Japanese approval submission for the fourth quarter of 2026 or first quarter of 2027, and a Helix FDA De Novo submission for the first quarter of 2027; it expects mid-2027 approval if the FDA meets its review target.
